US biopharmacy company AbbVie to buy Botox maker Allergan for around $63bn

US biopharmacy company AbbVie said on Tuesday it had agreed to buy Allergan, the maker of Botox, in a stock and cash operation worth about $63 billion.

The offer represents a 45 percent premium over Monday's share price of Irish-registered Allergan, whose management recommended the operation to shareholders.